# Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.

> **NCT07593482** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Swiss Cancer Institute** · enrollment: 92 (estimated)

## Conditions studied

- B-cell Lymphoma

## Interventions

- **DRUG:** bendamustine hydrochloride
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT07593482
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2029-03
- **Final completion:** 2030-03
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07593482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07593482, "Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT07593482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*